ONC releases wave five of 2014 draft test procedures

Editorial Staff | | Health Exec | Policy & Regulations

The Office of the National Coordinator for Health IT (ONC) published wave five of the draft test procedures for the 2014 edition of EHR certification criteria and is inviting the public to comment.

The procedures, which are intended to be finalized and published by early 2013, will be used by testing laboratories and certification bodies authorized by the ONC HIT Program to determine EHR systems’ compliance with standards established by the Department of Health and Human Services.

The public comment period for wave five draft test procedures will last for the two weeks following their publication date, Oct. 18. Specific criterion are listed on the ONC website and include:

  • Transitions of care;
  • Electronic prescribing;
  • View, download and transmit to third party; and
  • Inpatient setting transmission of reportable laboratory results.

Editorial Staff

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.